Don’t miss the latest developments in business and finance.

Natco Pharma launches breast cancer treatment drug Lapatinib Tablet in US

Image
Capital Market
Last Updated : Sep 30 2020 | 7:50 PM IST

Through its marketing partner - Lupin

Natco Pharma announced that its marketing partner, Lupin has launched Lapatinib Tablets, 250 mg, in the United States market after NATCO received the final approval for its Abbreviated New Drug Application (ANDA) from the U.S. Federal Drug Administration (USFDA). NATCO was the 1st ANDA applicant for Lapatinib Tablets, 250mg, containing a Paragraph IV certification.

Lapatinib Tablets, 250mg, is sold under Brand name TYKERB, of Novartis Pharmaceuticals Corporation (Novartis), which is indicated primarily for the treatment of certain types of breast cancer.

For the 12 months ending June, 2020, TYKERB had sales of approximately USO 61 million in the U.S. (IQVIA MAT June 2020).

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Sep 30 2020 | 7:05 PM IST

Next Story